-
As ESG Investment Grows, An Asset Manager Looks to Futures
Friday, May 15, 2020 - 3:51pm | 1429Read More...Sustainability-focused funds have continued on an upward trajectory in 2020, despite a volatile first quarter. Morningstar research reveals that 24 of 26 environmental, social and governance (ESG)-tilted index funds outperformed their closest conventional counterparts in the first three months of...
-
Swedbank Downgrades Scorpio Tankers To Neutral
Wednesday, September 24, 2014 - 8:11am | 59Read More...Analysts at Swedbank downgraded Scorpio Tankers (NYSE: STNG) from Buy to Neutral. The target price for Scorpio Tankers has been lowered from $12.50 to $9. Scorpio Tankers shares have declined 9.04% over the past 52 weeks, while the S&P 500 index has gained 17.13% in the same period. Scorpio...
-
Swedbank Initiates Golar LNG At Buy
Tuesday, September 9, 2014 - 8:45am | 59Read More...Analysts at Swedbank initiated coverage on Golar LNG (NASDAQ: GLNG) with a Buy rating. The target price for Golar LNG is set to $85. Golar LNG shares have jumped 60.64% over the past 52 weeks, while the S&P 500 index has surged 19.73% in the same period. Golar LNG's shares surged 4.04% to...
-
UPDATE: Swedbank Downgrades Nokia on Excessive Share Price Gains
Tuesday, July 9, 2013 - 9:28am | 116Read More...In a report published on Tuesday, Swedbank analyst Håkan Wranne downgraded Nokia (NYSE: NOK) from Buy to Neutral and maintained a price target of $3.86 (3 Eur). In the report, Swedbank noted, "Following the acquisition of Siemens' 50% stake in NSN, Nokia has reached and exceeded our EUR 3.0...
-
UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure
Friday, March 8, 2013 - 8:34am | 75Read More...Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell. Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together...
-
UPDATE: Swedbank Downgrades AstraZeneca to Reduce on Valuation
Friday, October 26, 2012 - 7:15am | 84Read More...Swedbank lowered its rating on AstraZeneca (NYSE: AZN) from Neutral to Reduce as the company faces price pressures ahead. Swedbank commented, "Increasing the focus on productivity and innovation is exciting, but after spending USD 23bn over 5 years, execution and transparency is critical. AZN is...

